[1]
Plunkett, W. 2009. Rationale for the design of combination therapies that are active in T-cell lymphomas?. Hematology Meeting Reports (formerly Haematologica Reports). 2, 13 (Jun. 2009). DOI:https://doi.org/10.4081/hmr.v2i13.498.